1. Background
=============

Fanconi syndrome (FS) is a rare metabolic disease identified by dysfunction of the renal proximal tubules. The low reabsorption capacity of the proximal tubules results in the abnormal urinary excretion of several metabolites, including phosphate, glucose, amino acids, uric acid, and various ions. Other biochemical findings include hypokalemia, hypouricemia, and metabolic acidosis ([@A3723REF1], [@A3723REF2]). This syndrome is highly associated with osteomalacia, osteoporosis, muscle weakness, and severe bone pain. The production of monoclonal light chains, especially kappa chains, which have toxic effects on the renal tubules, is also reported in these patients ([@A3723REF3]).

FS may be a genetic disease with primary or secondary causes, or may be acquired. A missense mutation in sodium phosphate cotransporter (NaPi-II) of the proximal tubular apical membrane accounts for primary FS. This syndrome may also develop secondary to systemic disease. The genetic and acquired causes of FS are indicated in [Table 1](#A3723TBL1){ref-type="table"}. The causes of FS may also lead to renal tubular acidosis. Light-chain-associated FS is the most frequent among the acquired factors ([@A3723REF4]).

###### Genetic and Acquired Causes of Fanconi Syndrome ([@A3723REF4])

  Primary                                        Missense Mutation of NaPi-II Cotransporter
  ---------------------------------------------- -------------------------------------------------------------------------------------
  **Secondary to inherited systemic diseases**   
                                                 Cystinosis
                                                 Tyrosinemia
                                                 Hereditary fructose intolerance
                                                 Galactosemia
                                                 Glycogen storage disease (type I)
                                                 Mitochondrial disorders
                                                 Wilson's disease
                                                 Lowe's syndrome
                                                 Den's disease
                                                 Fanconi-Bickel syndrome
  **Acquired**                                   
                                                 Drugs (tenofovir, ifosfamide, cisplatin, valproic acid, aminoglycosides, cidofovir)
                                                 Heavy metals
                                                 Multiple myeloma
                                                 Amyloidosis
                                                 Vitamin D deficiency
                                                 Renal transplantation
                                                 Paroxysmal nocturnal hemoglobinuria

Dysglobulinemia is a feature of FS, and some studies in the literature report FS in association with myeloma, amyloidosis, and Bence-Jones proteinuria ([@A3723REF5]). In this study, we report a unique case of FS that was complicated by bilineal acute leukemia with myeloid and T-lymphoid lineages.

2. Case Presentation
====================

An 8-year-old boy was admitted to our center complaining of pallor, anemia, asthenia, and recurrent infections in January 2014. The patient was the first child of a family with three children. Physical examination revealed severe growth failure, with a weight of 12 kg weight, height of 97 cm, and head circumference of 46 cm. Hepatosplenomegaly was observed with a palpable liver and spleen 3 cm and 2 cm below the costal margin, respectively. On abdominal ultrasound, the sizes of the liver and spleen were 95 mm and 86 × 40 mm, respectively, and an echogenic focus in the left kidney was also detected. The patient presented with genu valgum and was not able to walk easily. Bilateral cataracts and lens opacity were found, with 6/10 and 7/10 visual acuity for the right and left eyes, respectively. Wrist radiography showed widening, fraying, and cupping, all suggestive of rickets, and bone age was 3.5 years. Complete blood count (Sysmex KX 21N, Japan) demonstrated a white blood cell count of 4.2 × 10^9^/L with 87% lymphocytes, a hemoglobin level of 4.9 g/dL, mean corpuscular volume of 74 fl, and a platelet count of 73×10^9^/L. The erythrocyte sedimentation rate was 104 mm/hr. The ferritin level was extremely high (2250 ng/mL; normal range is 12 - 142 for children). Venous blood gas analysis (ABL 735; Radiometer, Copenhagen, Denmark) was as follows: pH 7.30, pCO~2~ 29 mmHg, HCO~3~ 13 Meq/L, BE 10 Meq. Liver function tests, thyroid function tests, and evaluation for celiac disease by tissue transglutaminase IgA antibody (TTG IgA) were normal. The results of biochemical testing (Hitachi 917, Hitachi, Japan) are summarized in [Table 2](#A3723TBL2){ref-type="table"}.

###### Biochemical Test Results for the Patient

  Test                              Result      Normal Values      Low/Normal or High According to Normal Values
  --------------------------------- ----------- ------------------ -----------------------------------------------
  **Blood sugar (BS)**              91 mg/dL    70 - 110 mg/dL     Normal
  **Blood urea nitrogen (BUN)**     9 mg/dL     7 - 18 mg/dL       Normal
  **Serum creatinine (Cr)**         0.7 mg/dL   0.6 - 1.2 mg/dL    Normal
  **Sodium (Na)**                   137 mEq/L   135 - 145 mEq/L    Normal
  **Potassium (K)**                 3.3 mEq/L   3.5 - 5.0 mEq/L    Low
  **Calcium (Ca)**                  8.7 mg/dL   8.4 - 10.2 mg/dL   Normal
  **Uric acid**                     1.7 mg/dL   3.0 - 8.2 mg/dL    Low
  **Lactate dehydrogenase (LDH)**   463 U/L     45 - 90 U/L        High
  **Phosphorus (P)**                1.1 mg/dL   3.0 - 4.5 mg/dL    Low

Immunologic analysis revealed a low IgG level (6 g/L, normal 6.46 - 14.51) but high IgM (2.7 g/L, normal 0.55 - 2.32) and IgA (2.3 g/L, normal 0.28 - 2.22). C-reactive protein was 3^+^ on the latex agglutination test. Urine analysis showed glucosuria and proteinuria, with a pH of 5. According to the physical examination results, clinical manifestations, radiologic findings, and laboratory results, FS was diagnosed. On microscopic examination of the bone marrow aspirate (BMA), two different populations of blasts were observed ([Figure 1](#A3723FIG1){ref-type="fig"}). Subsequent flow cytometric analysis (Partec, CyFlow® Space) revealed 98% blasts with positivity for CD2, cytoplasmic CD3, CD7, TdT, CD13, CD34, CD117, and myeloperoxidase. Common chromosomal translocations of acute leukemia, including t(4,11), t(12,21), t(1,19), and t(9,22) by the PCR method were all negative. According to the world health organization (WHO) 2008 classification ([@A3723REF6]), these findings are indicative of a bilineal acute leukemia with myeloid and T-lymphoid lineages.
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Cerebrospinal fluid analysis and cytology was normal. The patient received Joulie's solution for the FS, and a combined chemotherapy regimen that was effective for both acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) (modified by the St. Jude XIII-B high risk protocol) ([@A3723REF7]). Despite supportive treatments and administration of wide spectrum antibiotics, the patient died at the end of the induction phase of chemotherapy due to sepsis and disseminated intravascular coagulation (DIC). Further examinations of family members revealed that the patient's 4-year-old sister was similarly diagnosed with FS. The third child of this family, a newborn baby, was not investigated.

3. Discussion
=============

Given that dysglobulinemia is a feature of FS, it may be commonly associated with myeloma, amyloidosis, and Bence-Jones proteinuria ([@A3723REF5]). Ma et al. suggested acquired FS as a complication of monoclonal gammopathy in adults ([@A3723REF8]). Messiaen et al. reported several cases of multiple myeloma that subsequently developed FS ([@A3723REF9]). Rochman et al. reported a case of FS as the result of chronic lymphocytic leukemia ([@A3723REF10]). There is also a study by Bridoux et al. reporting the development of FS in a patient with Waldenström's macroglobulinemia ([@A3723REF11]). The authors suggested that the accumulation of kappa light chains may have played a significant role in the development of FS in the reported patients ([@A3723REF9], [@A3723REF11]). Another study reported a case with chronic myelogenic leukemia, who developed partial FS after receiving imatinib mesylate (Gleevec) ([@A3723REF12]).

Considering the familial occurrence and the childhood onset of FS in our patient, an inherited background is probable. The unusual event in our patient is the development of an almost rare acute leukemia, a condition which has not been reported before.

Although the majority of acute leukemias can be classified as myeloid, B lymphoid, or T lymphoid lineages through morphology, immunophenotyping, cytogenetic, and molecular analyses, there are also rare cases that manifest the characteristics of at least two lineages and account for 2% - 5% of all acute leukemias ([@A3723REF13]). Generally, two main types can be located in this group: biphenotypic leukemia and bilineal leukemia. The former refers to leukemias in which divergent features present in a single blast population, while the latter describes leukemias with two different populations of blasts ([@A3723REF14]). In the WHO 2008 classification, both types are termed as mixed-phenotype acute leukemia (MPAL) ([@A3723REF6]). The lineage-specific markers suggested by the WHO 2008 are listed in [Table 3](#A3723TBL3){ref-type="table"}. Accordingly, positivity of myeloperoxidase and cytoplasmic CD3 in either a single or distinct population of blasts (as was found in our patient) are sufficient for a diagnosis of MPAL with T/myeloid differentiation. In this classification, MPAL with BCR-ABL1 fusion or MLL gene rearrangements with the most common partner gene, AF4 at the 4q21 location, have been regarded as separate entities ([@A3723REF6]).

In our patient, there was no evidence of t(9,22)(q34;q11), which leads to BCR-ABL1 fusion, or of t(4,11)(q21;q23), which most commonly involves the MLL gene. Meeting the WHO 2008 criteria, MPAL T/myeloid, not otherwise specified was the diagnosis in our patient.

###### WHO 2008 Classification of Mixed-Phenotype Acute Leukemias ([@A3723REF6])

  Lineage          Markers
  ---------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Myeloid**      Myeloperoxidase Or Monocytic differentiation (at least two of the following: non-specific esterase, CD11c, CD14, CD64, lysozyme)
  **T lymphoid**   Cytoplasmic CD3 or Surface CD3
  **B lymphoid**   Strong CD19 and at least one of the following with strong expression: CD79a, cytoplasmic CD22, or CD10 or Weak CD19 and at least two of the following with strong expression: CD79a, cytoplasmic CD22, or CD10

Like other acute leukemias, the clinical presentations of MPAL are mainly a result of BM failure, and according to the literature, these include fatigue, infections, and bleeding disorders ([@A3723REF6]). Hepatosplenomegaly, thrombocytopenia, and severe anemia with high levels of ferritin in our patient were supportive of BM failure, but no bleeding tendency was found. According to the published studies, the outcome of MPAL is generally poor ([@A3723REF15]). The study by Lee et al. indicated that patients with myeloid/T-lymphoid have an even lower chance of survival than patients affected by the rest of the MPALs ([@A3723REF16]). Currently, there is no agreement on the treatment of MPAL patients, but a chemotherapy regimen effective for both AML and ALL has been suggested ([@A3723REF6]). However, Killick et al. noted that such a therapeutic protocol is associated with a high rate of early death in these patients ([@A3723REF17]). Consistent with the therapeutic strategy elected for in the study by Al-Seraihy et al. we chose the modified St. Jude XIII-B high-risk protocol for our patient, since they suggested that this type of therapy is effective at gaining and maintaining complete remission ([@A3723REF18]).
